Ebola in DR Congo: The 1976–2026 Outbreak History and Timeline

Every large Ebola response since 2018 has leaned on one tool above all others: ring vaccination with Ervebo, the rVSV-ZEBOV vaccine that helped bring the 2018-2020 Kivu epidemic under control. That tool does not exist for this outbreak. Bundibugyo virus is a genetically distinct Ebola species from Zaire ebolavirus, and while both cause the same underlying disease — Ebola virus disease — a vaccine built around one species’ surface proteins cannot be assumed to protect against another’s. CEPI, the vaccine-development coalition now funding Bundibugyo-specific candidates, has been explicit on this point: there are no licensed vaccines for Bundibugyo virus, only candidates in preclinical or early clinical testing.

That gap arrived at the worst possible moment. The outbreak began in Mongbwalu, a health zone in Ituri Province known for high-traffic artisanal gold mining, in a corner of the country where the ADF, CODECO and other armed groups already restrict movement and where over 270,000 people were displaced before a single Ebola case was confirmed. Contact tracing — the tool that had made the 2022 one-case North Kivu outbreak a two-month success story — struggled from the outset: WHO’s own 21 May 2026 update recorded only a 21% contact follow-up rate in Ituri, and the International Rescue Committee warned by early June that only about one in five contacts were being located at all.

The result was not a slower version of 2018-2020. It was faster. Médecins Sans Frontières described it in mid-July as “the third largest, and fastest growing, Ebola disease outbreak on record.” By early August, WHO was calling it the second-largest Ebola outbreak in history, behind only the 2014-2016 West African epidemic. By mid-August, it had killed more people than any Ebola outbreak DRC had ever recorded.

Ebola virus disease is a severe, often fatal illness caused by viruses in the genus Orthoebolavirus. Scientists currently recognize six species: Zaire ebolavirus (the species behind most historical outbreaks, including 1976, 1995, 2014-2016 and 2018-2020), Sudan ebolavirus, Bundibugyo virus, Tai Forest virus, Reston virus (which has not been shown to cause human disease) and Bombali virus. All cause a broadly similar clinical picture and all spread the same way — through direct contact with the blood, body fluids or contaminated materials of an infected person or animal, not through the air. But they are genetically distinct enough that immunity, vaccines and some treatments built for one species cannot be assumed to protect against another.

Bundibugyo virus (formally Orthoebolavirus bundibugyoense) was unknown to science until November 2007, when an unusual hemorrhagic-fever outbreak in Uganda’s Bundibugyo District turned out to be caused by a virus roughly 32% genetically divergent from Zaire ebolavirus — different enough to be classified as a new species entirely. In its two confirmed outbreaks before 2026 — Uganda in 2007-2008 and DRC’s Isiro in 2012 — Bundibugyo virus showed a historical case-fatality rate in the range of roughly 25-50%, comparable to Zaire ebolavirus’s own range across different outbreaks. It is not a milder virus. It is simply a far less studied one, with a far thinner research and countermeasure base behind it, because both of its prior outbreaks were small.

Each generation of Congo’s Ebola outbreaks has strengthened, or exposed a weakness in, a different link in that chain. 1976 taught the world about isolation and infection control. 1995 proved field epidemiology and barrier nursing could stop hospital-driven spread. 2007 forced virus identification itself to expand beyond a single known species. 2014-2016 turned a regional health crisis into a genuinely global one, and built the vaccine the world now depends on. 2018-2020 proved that vaccination and contact tracing could work even inside an active war zone. 2022’s one-case outbreak showed what near-perfect detection and containment look like. 2025’s Bulape outbreak proved that surveillance built since 2018 could still catch a new spillover fast, in one of the country’s more remote provinces. 2026 is testing the two links the chain has always depended on most and prepared for least: whether community trust and cross-border cooperation can hold up when the vaccination link is missing entirely.

No treatment stopped the 1976 outbreak. What stopped it was infection control: isolating patients, sterilizing or discarding needles instead of reusing them, and international field epidemiologists working alongside Zairian health workers to trace every chain of transmission by hand. That lesson — that a hospital can be an outbreak’s engine if basic barrier practices fail, and its brake if they hold — is the oldest link in the Ebola Response DNA framework above, and it is still being relearned today: four of the 2026 outbreak’s earliest deaths were health workers infected at Mongbwalu General Referral Hospital.

Ituri sits in DRC’s northeast corner, bordering Uganda, threaded by roads that are often impassable in the rainy season and, in several territories, controlled or contested by armed groups rather than the state. It is also home to significant artisanal gold, tin, tungsten and tantalum mining, which draws a constantly shifting population of workers between mine sites and home villages. According to WHO’s 21 May 2026 update, Ituri had 273,403 internally displaced people and 1.9 million people in humanitarian need even before the outbreak began — a population already stretched thin on health access, clean water and food security. By WHO’s 14 August 2026 report, Ituri still accounted for 85% of all confirmed cases (3,979 of 4,665) and 79% of deaths (1,726 of 2,184), even as the outbreak had spread to five other provinces. None of that makes the people of Ituri responsible for the outbreak’s scale; it explains why an outbreak that might have been contained in a stable, accessible region instead found a landscape almost perfectly suited to outrunning the response built to stop it.

The outbreak’s first confirmed cluster emerged in Mongbwalu, which WHO’s own outbreak report describes as “a high-traffic mining area.” Mining activity itself did not cause the outbreak — Ebola’s animal reservoir, not human industry, is the source of every spillover event. But artisanal mining sites concentrate large numbers of workers from many different villages in close quarters, often with limited sanitation, and those workers move frequently between mine sites and home communities. That mobility can complicate containment by making contact tracing harder: a contact identified in one village may already have traveled to a mine site in another health zone, or a different province entirely, by the time a tracing team arrives. It is one part of the explanation, alongside conflict and weak baseline health infrastructure, for why the outbreak spread to 55 health zones across six provinces rather than staying contained near its point of origin.

Every link in the Ebola Response DNA chain — detection, contact tracing, safe burial, vaccination, surveillance — depends on response teams physically reaching the people who need them. In parts of Ituri and North Kivu affected by this outbreak, armed groups including the ADF and CODECO, and the wider M23-linked conflict active in the region since 2022, have restricted that access directly. WHO’s 21 May 2026 update cited “ongoing conflict in Ituri province restricting the movement of surveillance teams” as a direct factor in the outbreak’s early spread. This is not a new problem for DRC’s Ebola responses: the 2018-2020 Kivu outbreak was the first ever fought inside an active conflict zone, and attacks on health facilities and workers during that response are well documented. What is different in 2026 is that this conflict-driven access problem is compounding a second, simultaneous handicap — the absence of a proven vaccine — that the 2018-2020 response did not have to face.

Uganda declared its own outbreak on the same day as DRC, 15 May 2026, after confirming cases linked to the DRC cluster. WHO’s early reporting described Uganda’s cases as imported from DRC, with no confirmed local transmission chain established inside Uganda itself; by the time of that reporting, two confirmed cases and one death had been recorded in Kampala. Uganda closed its border with DRC for four weeks starting 27 May and required a 21-day isolation period for arrivals from affected areas, alongside contact-monitoring of 127 identified contacts. The Uganda outbreak proved short-lived by outbreak standards: its last patient was discharged from care on 16 July 2026, with no confirmed active cases remaining, closing out a national outbreak of 20 confirmed cases and 2 deaths — a striking contrast to the outbreak’s trajectory across the border in DRC.

Every number in this article’s timeline exists because a health worker collected it, often at real personal risk. WHO’s 14 August 2026 update recorded at least 155 confirmed Ebola cases and 45 deaths among health workers — a case-fatality rate of roughly 29%, and the earliest of those deaths, four in total, occurred at Mongbwalu General Referral Hospital within a four-day span in May, before the outbreak had even been declared. Contact tracers, laboratory technicians, ambulance drivers, burial teams and vaccination staff have continued working through an active conflict zone, in a province with hundreds of thousands of displaced people, often in health zones with only partial contact-tracing coverage. Their work is the least visible part of the Ebola Response DNA framework and, historically, the part every successful outbreak response has depended on most.

By mid-August 2026, WHO and UN reporting put roughly 730 people in isolation or hospital care and around 1,040 recovered, alongside more than 2,325 deaths. Each of those figures represents a household disrupted: a caregiver who may themselves now be a contact under monitoring, children who have lost one or both parents, and survivors who face weeks of recovery and, in some cases, lingering health effects and social stigma after discharge. The International Rescue Committee warned in early June 2026 that the outbreak’s true scale was “likely far worse” than official figures, citing contact-tracing coverage of only about 20% in the hardest-hit areas — a reminder that official counts, however carefully sourced, are very likely an undercount of the true human toll in a conflict-affected, high-mobility region.

Health facilities in parts of Ituri and North Kivu are hours away over poor or conflict-affected roads. Treatment centers, however well run, mean separation from family at a moment of acute fear, and a documented history — both in this outbreak and in 2018-2020 — of misinformation and, at times, violence directed at health facilities and workers. WHO itself has cited “distrust of medical authorities” as a factor slowing this outbreak’s response, and more than 150 patients are reported to have left treatment facilities against medical advice since late May 2026, in some cases citing food shortages at the centers themselves. None of this reflects a community failing to understand the disease; it reflects a set of real, often reasonable, competing pressures — economic survival, family obligation, fear of an unfamiliar and frightening treatment setting — that every Ebola response has to work with, not against.

A confirmed diagnosis, a validated vaccine and a fully staffed treatment center accomplish little if the people who need them do not trust the system offering them. Every successful Ebola response since 1995 has depended on local religious and community leaders, Ebola survivors speaking to their own communities, and community health workers who live in the areas they serve, translating both the science and the reasons behind unfamiliar and frightening procedures — isolation, burial teams in protective suits, contact monitoring — into terms a frightened community can accept. That work cannot be replaced by a laboratory result or a vaccine dose; it is negotiated, person to person, and it is the layer of the Ebola Response DNA framework most directly damaged when conflict, displacement and misinformation are all present at once, as they are in Ituri in 2026.

A person who has died of Ebola remains highly infectious, and traditional burial practices in many Congolese communities involve washing, dressing and directly touching the body — precisely the contact that can transmit the virus. That is a scientific fact about transmission risk, not a judgment on the practices themselves, which carry deep cultural and religious meaning around grief and dignity. The response DRC and its partners have built over successive outbreaks is “safe and dignified burial”: trained teams who manage the infection-control aspects of burial while working to preserve as much of a family’s ability to participate in a meaningful send-off as safely possible, rather than simply prohibiting traditional rites outright. Programs that skip the “dignified” half of that phrase, and treat burial purely as a biohazard-containment problem, have historically driven more resistance and hidden, unsafe burials — the opposite of what the response needs.

Ebola spreads through direct contact with the blood or body fluids of a person who is sick with or has died from the disease, through contact with contaminated objects such as needles or bedding, and through contact with infected animals, particularly certain species of fruit bats believed to be the natural reservoir. It can also spread through certain body fluids of male survivors for a period after recovery, which is why survivor-monitoring and safe-sex counseling remain part of the response even after a patient is declared virus-free in blood. Ebola viruses are not respiratory viruses and do not spread through casual airborne contact — you cannot catch Ebola by sitting near someone on a bus or being in the same room as someone incubating the virus who has no symptoms.

Early Ebola symptoms — fever, fatigue, muscle pain, headache and sore throat — overlap heavily with malaria, typhoid and many other common illnesses in Central Africa, which is part of why early detection is so difficult. Later symptoms can include vomiting, diarrhea, rash, impaired kidney and liver function, and, in some cases, bleeding, though not every patient develops hemorrhagic symptoms and their absence does not rule out Ebola. Diagnosis requires a laboratory test (typically RT-PCR) on a blood sample; symptoms alone cannot confirm or rule out the disease. Treatment centers on early, aggressive supportive care: intravenous fluids and electrolyte correction, oxygen and blood-pressure support, and treatment of secondary infections, all of which meaningfully improve survival odds when started early. For Zaire ebolavirus specifically, two monoclonal antibody treatments (Inmazeb and Ebanga) have regulatory approval; neither has been shown effective against Bundibugyo virus, which is why the 2026 response is instead trialing remdesivir and different monoclonal antibody candidates (including MBP-134 and maftivimab) under WHO-sponsored research protocols rather than deploying an approved standard of care.

Ervebo (rVSV-ZEBOV) was developed and clinically tested at accelerated pace during and after the 2014-2016 West African epidemic, using a ring-vaccination trial design in Guinea that showed strong efficacy against Zaire ebolavirus. It received its first regulatory approvals in 2019 and was deployed at large scale during DRC’s 2018-2020 Kivu outbreak, protecting contacts and contacts-of-contacts and, by most expert assessments, playing a central role in eventually ending that epidemic. That success is precisely why its absence matters so much in 2026: Ervebo’s efficacy is specific to Zaire ebolavirus’s surface proteins, and there is not yet sufficient evidence that it cross-protects against Bundibugyo virus. WHO’s guidance since May 2026 has treated it as a research candidate for this outbreak, not a proven preventive tool, which is why the emphasis of the 2026 vaccine response has shifted to accelerating entirely new, Bundibugyo-specific candidates instead.

1. Symptom onset: Fever and fatigue begin, indistinguishable at first from malaria or typhoid — the earliest and hardest point to detect Ebola specifically.
2. Family: A household decides whether to seek care immediately, or to wait, weighing distance, cost, fear of a treatment center and the illness’s ambiguous early symptoms.
3. Health facility: If reached, a clinic or hospital must recognize the possibility of Ebola, isolate the patient, and notify surveillance authorities — a step that can fail if the facility is remote, under-resourced, or the patient never arrives at all.
4. Laboratory: A blood sample must reach a lab capable of RT-PCR testing, often requiring transport across difficult or insecure terrain, to confirm the diagnosis.
5. Contact tracing: Every person the patient had contact with while infectious must be identified and monitored for 21 days — the step WHO recorded at only 21% coverage in Ituri in May 2026.
6. Community: Neighbors, local leaders and community health workers determine whether the response is trusted or resisted, shaping whether contacts come forward voluntarily.
7. Border: If the patient or a contact has crossed into another country, cross-border health authorities must coordinate screening and data-sharing in real time.
8. Surveillance: Even after a patient recovers or dies, the system must keep watching for weeks, since survivors, funerals and hidden contacts can all silently restart transmission.

Every one of the outbreak’s headline numbers — 4,945 confirmed cases, a 21% contact follow-up rate, 55 affected health zones — is the sum of thousands of individual patients moving through some version of that eight-step path, succeeding or stalling at a different point each time.